NIOX Group Plc (CSSPF)
OTCMKTS · Delayed Price · Currency is USD
0.9200
+0.2300 (33.33%)
At close: Jun 9, 2025
NIOX Group Revenue
NIOX Group had revenue of 25.20M GBP in the half year ending June 30, 2025, with 34.04% growth. This brings the company's revenue in the last twelve months to 46.00M, up 21.37% year-over-year. In the year 2024, NIOX Group had annual revenue of 41.80M with 13.59% growth.
Revenue (ttm)
46.00M GBP
Revenue Growth
+21.37%
P/S Ratio
5.90
Revenue / Employee
505.49K GBP
Employees
91
Market Cap
371.79M USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 41.80M | 5.00M | 13.59% |
| Dec 31, 2023 | 36.80M | 5.50M | 17.57% |
| Dec 31, 2022 | 31.30M | 3.40M | 12.19% |
| Dec 31, 2021 | 27.90M | 4.00M | 16.74% |
| Dec 31, 2020 | 23.90M | -10.70M | -30.92% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zomedica | 29.45M |
| OpGen | 9.00M |
| Tian'an Technology Group | 2.12M |
| PetVivo Holdings | 1.41M |
| Positron | 486.45K |
| Guided Therapeutics | 178.00K |
| CS Diagnostics | 98.73K |
| Vivos | 48.62K |